chrisvoncsefalvay/vaers-outcomes huggingface dataset:
COVID-19; hair loss; possible issue in her lungs; pain in her breast; her lymph nodes were super swollen/still very swollen; 1st dose of Moderna COVID-19 Vaccine on 20Aug2021 and 2nd dose on 10Sep2021; This spontaneous case was reported by a patient and describes the occurrence of COVID-19 (COVID-19), BREAST PAIN (pain in her breast), ALOPECIA (hair loss), LUNG DISORDER (possible issue in her lungs) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (1st dose of Moderna COVID-19 Vaccine on 20Aug2021 and 2nd dose on 10Sep2021) in a 57-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 037F21A and 062E21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient had no allergies. Patient had no history relating to mentioned adverse event and both Acute and Chronic illnesses at the time of vaccination. Patient had not received other vaccines within 1 month prior to Moderna COVID-19 vaccine.    On 20-Aug-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 10-Sep-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 10-Sep-2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (1st dose of Moderna COVID-19 Vaccine on 20Aug2021 and 2nd dose on 10Sep2021). In November 2021, the patient experienced BREAST PAIN (pain in her breast) and LYMPHADENOPATHY (her lymph nodes were super swollen/still very swollen). On 14-Feb-2022, the patient experienced COVID-19 (COVID-19). In 2022, the patient experienced ALOPECIA (hair loss) and LUNG DISORDER (possible issue in her lungs). The patient was treated with VITAMIN E [VITAMIN E NOS] at a dose of 40 milligram. At the time of the report, COVID-19 (COVID-19) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (1st dose of Moderna COVID-19 Vaccine on 20Aug2021 and 2nd dose on 10Sep2021) outcome was unknown and BREAST PAIN (pain in her breast), ALOPECIA (hair loss), LUNG DISORDER (possible issue in her lungs) and LYMPHADENOPATHY (her lymph nodes were super swollen/still very swollen) had not resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In November 2021, Mammogram: lymph nodes were super swollen. In November 2021, Ultrasound breast: lymph nodes were super swollen. On 14-Feb-2022, SARS-CoV-2 test: Positive. In 2022, Mammogram: lymph nodes were still very swollen.         Patient was not under any regular or concomitant medication. Patient had not experienced a similar event in the past. The patient was also experiencing a possible issue in her lungs, but she would visit a specialist soon. Symptoms were still ongoing, recently another mammography showed that lymph nodes were still very swollen. Treatment given was Vitamin E 40 mg and she had to use a sport bra. Doctors tried to do a biopsy but it was not possible. Patient got COVID-19 but she had not felt bad and was isolated during 1 week. Patient visited gynecologist and breast oncologist.
Lot number was expired. Patient tolerated well. Per Moderna, the vaccine administered maintained its activity necessary to protect against the COVID 19 virus at the time of administration.
Patient came back at 12:50PM same day + complaint That he is feeling brown spot Floating in front of his right eye. No pain/itching/redness. That was the Ist time he received the Flu shot  Adviced patient to wash his eye + rest. If symptoms didn't resolve. Then call us + see eye doctor.
This is a prospective pregnancy case. This 29-year-old female subject was enrolled in an open label study: a prospective, exploratory, cohort study to detect and describe any abnormal pregnancy outcomes in women intentionally or unintentionally vaccinated with BOOSTRIX during pregnancy or within 28 days preceding conception. The subject received BOOSTRIX (intramuscular) .5 ml on 26th November 2014. The subject's last menstrual period was on 18th April and estimated date of delivery was 14th January 2015. The subject received BOOSTRIX at week 31 of the pregnancy and during the third trimester of pregnancy. On an unknown date, an unknown time after receiving BOOSTRIX the subject developed vaccine exposure during pregnancy (Non-serious). The outcome of vaccine exposure during pregnancy was unknown. The pregnancy was ongoing. Additional information received on 05 December 2014: It was unknown if the patient was using contraceptive method. The type of conception was normal and there was no evidence of defect from prenatal testing. The patient had one previous pregnancy with normal birth and without birth defect. It was also unknown if there was any maternal history which may have an impact on the outcome of this pregnancy, if she experienced adverse event and if the father had a relevant medical or family history. The number of gestational weeks at vaccination was not reported but was calculated with the last menstrual period.
Adolescent received Moderna COVID-19 vaccine/child was too young; This spontaneous case was reported by an other health care professional and describes the occurrence of PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (Adolescent received Moderna COVID-19 vaccine/child was too young) in a 14-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 020B21A and 014F21A) for COVID-19 vaccination.     No Medical History information was reported.   On 02-Aug-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 17-Sep-2021 at 11:00 AM, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 02-Aug-2021, the patient experienced PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (Adolescent received Moderna COVID-19 vaccine/child was too young). On 02-Aug-2021, PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (Adolescent received Moderna COVID-19 vaccine/child was too young) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter considered PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE (Adolescent received Moderna COVID-19 vaccine/child was too young) to be possibly related.    No concomitant medications were provided. No treatment medications were reported. It was reported that   Moderna  instructed that if the child was between the ages of 12-17 that the second dose of Moderna covid vaccine should be given following 28 days from the first dose and hence the second dose was given.   Most recent FOLLOW-UP information incorporated above includes: On 21-Sep-2021: Significant follow-up appended: Patient demographics, dose 1 and 2 details, event details added.
rt thigh red & swollen, non-tender;walks normally;Ibuprofen for swelling;
Wednesday night on 3/11/2021 around 9 pm dull chest pain under and around left breast.  Called doctor on Thursday morning.  Spoke with Dr  in the afternoon.  Office visit on Saturday morning.  Administered EKG ... diagnosis ...  Pericarditis ... prescribed Famotidine 40mg and Naproxen 250mg.
Few hours after vaccine developed fevers for 2 days which resolved. Then 6/2/21 developed fevers, rash, chest pain, admitted to hospital 6/4/21 with fevers, rash, pancytopenia, pericarditis, myocarditis
Narrative:  PATIENT WAS VACCINATED IN A TIMELY MANNER IN JAN/FEB 2021 WITH PFIZER. PT WAS ADMITTED 8-17-21 AFTER PRESENTING TO ER WITH COUGH, CHEST CONGESTION, DIARRHEA AND TACHYCARDIA. PATIENT WAS PROVIDED O2 BRIEFLY FOR TACHYCARDIA AND FOR COMFORT WHILE SLEEPING (NO CPAP MACHINES AVAILABLE)
Ringing in the ears is loud, unabated and distracting; Ringing in the ears is loud, unabated and distracting; This is a spontaneous report from a contactable consumer, the patient. A 61-year-old male patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6207) via an unspecified route of administration in the left arm on an unknown date (at the age of 61-years-old) and second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER87729) via an unspecified route of administration in the left arm on an unknown date (at the age of 61-years-old) as a single dose for COVID-19 immunisation. The patient had no relevant medical history. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient did not receive any other medicines within two weeks prior to the COVID-19 vaccine. On 11Mar2021 at 06:00, the patient experienced ringing in the ears is loud, unabated and distracting. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event ringing in the ears is loud, unabated and distracting was not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
This spontaneous report as received from a registered nurse refers to an unspecified number of patients of unknown age and gender. No information on patients medical history or concurrent conditions was provided. On an unknown dates in approximately June 2015 (reported as since 06/11/2015), the patients were vaccinated with a doses of VARIVAX (Merck) subcutaneous injection (strength, dose, lot# and expiration date were not reported) which were improperly stored. No information on patients concomitant medication was provided. No adverse effects were reported. Product quality complaint (PQC) was not involved. This is one of several reports from the same reporter. Additional information has been requested.
Menveo was given to a 65 year old patient; Menveo was given instead of Menquadfi in a 65 year old patient; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of inappropriate age at vaccine administration in a 65-year-old female patient who received Men ACWY-CRM NVS (Menveo) (batch number AMVA934A, expiry date 06-JUN-2024) for prophylaxis.   On 31-MAY-2023, the patient received the 1st dose of Menveo. On 31-MAY-2023, an unknown time after receiving Menveo, the patient experienced inappropriate age at vaccine administration (Verbatim: Menveo was given to a 65 year old patient) and wrong vaccine administered (Verbatim: Menveo was given instead of Menquadfi in a 65 year old patient). The outcome of the inappropriate age at vaccine administration and wrong vaccine administered were unknown.   Additional Information: GSK Receipt Date: 31-MAY-2023 A pharmacist called and reported that Menveo was given instead of Menquadfi in a patient and wished to know how to proceed.  The information about the event, vaccine and patient were given. The vaccine administration facility was the same as primary reporter. The reporter consented to follow up. A 65 year old patient received a dose of Menveo instead of Menquadfi, which led to wrong vaccine administered and inappropriate age at vaccine administration.
A few minutes after shot administered pt slumped in seat was unconscious for a short time. he came too was embarrassed said he felt fine but a few minutes after he stated he was not feeling well at all. pt became pale, extreme sweating, and low blood pressure/pulse with BP machine. at that time paramedics was called and arrived when patient was beginning to feel better. Paramedics offer to take to hospital but pt declined and could walk with not feelin dizzy. followed up with patient this evening and he is feeling much better. Patient contact his MD and discussed with him. His MD advised him to receive shot lying down for second shot.
Client was seated in the chair, appeared calm.  Moved away when needle went in - no vaccine administered.  Revaccination with new syringe/dose in the same arm.
POOR QUALITY VACCINE ADMINISTERED; INCORRECT STORAGE OF PRODUCT (VIAL WAS PUNCTURED AT 07:51, AND DOSE WAS GIVEN AT 14:50); This spontaneous report received from a health care professional concerned a patient of unspecified age and sex. The patient's height, and weight were not reported. No past medical history or concurrent conditions were reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 043A21A expiry: 05-AUG-2021) dose was not reported, administered on 11-JUN-2021 14:50 for prophylactic vaccination. No concomitant medications were reported. On 11-JUN-2021, the subject experienced poor quality vaccine administered. On 11-JUN-2021, the subject experienced incorrect storage of product (vial was punctured at 07:51, and dose was given at 14:50). The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of the poor quality vaccine administered and incorrect storage of product (vial was punctured at 07:51, and dose was given at 14:50) was not reported. This report was non-serious.
A pneumococcal vaccine was administered on 12/10 right deltoid. A few days ago patient states the area became itchy and the injection site area became red and swollen. Seen at today clinic on 12/17/15 diagnosed with a local reaction 5-6cm. Treatment: triamcinolone cream BID prn.
My side effects were body aches, very sore arm, fever of 100.3, headache, chills, and vomiting.
Hive / rash on in back of left knee, side of right calf, side of right knee,  one strip on upper right arm. Very mild spot in left inner thigh. Approximately beginning of May. Moisturized a lot and put Aloe Vera gel on. Almost all gone now, still a slight discoloration, mostly in back of left knee. July 2.
SEPT 1ST, 2021- 4pm administered a home covid 19 test, it was negative, at 5pm: Received first dose of Pfizer at Pharmacy. Waiting 30 minutes, no immediate reactions. Sept 2nd, 2021 at 10:30pm: Relaxing at home with my dog. Started Coughing, Tachycardia (180+ BPM),O2 sat 97%, Hypertension (BP 220/135) less than 30 seconds (results via pulses/ox meter, Electronic arm BP cuff), shaking tingling-numbness in upper and lower extremities. Went two houses down to mom and dad's and called 911, Ambulance came and paramedics did a patient assessment and confirmed the above. Recommended transport to emergency room. I agreed and was transported to ER. In route paramedic started an IV, took BP and confirmed very high BP with tachycardia, but O2 sat were normal and stayed normal, EKG performed which showed normal heart sinus arrhythmia. Paramedic administered 1 dose Nitroglycerin under the tongue, 1 dose of Morphine via IV, 1 dose of Zopran via IV.  This got my heart rate within normal limits and my BP down to a high normal, upon arriving at Emergency Room per the paramedic.  Admitted to ER around 12:00am Sept 3rd, 2021. Nurse performed another EKG and confirmed normal heart sinus arrhythmia, heart rate normal, BP normal, O2 normal.  ER doc ordered Covid 19 test and blood labs and 1 bag of saline solution with a dose of  Ativan I believe. Covid 19 test was negative, blood work normal according to the ER doc.  I was discharged around 5:30 am Sept 3rd, 2021. I didn't feel back to my normal self until Sunday, Sept 5, 2021. No other issues at this time. Heart rate and BP appear to be normal at this time. I have no history or diagnoses of any other medical issues other than hypertension.  I am concerned with the possible short and long term effects this may have on my health and well being.
Report 2001028372-1 describes a 54-year-old female who did not respond to the hepatitis B recombinant vaccine (Engerix-B) immunization series. Medical history, concurrent conditions and concurrent medications were not specified. The pt received injections of Engerix-B (lot ENG3212A4) on 01/03/1999, 02/03/1999 and 06/02/199, On an unspecified date, the pt "tested negative for any hepatitis B antibodies."
Patient reported she felt her blood pressure was going down 8 minutes after getting vaccinated. Patient complained of dizziness and palpitations. Vital signs were checked: 190/100(L) PR 121 HR was regular.  RR 20 BT 98.2.. Rechecked blood pressure: 160/98(R) PR 72. Called 911 at 3pm, and the patient reached her family. Rescue squads arrived at 3:08pm. Patient sent to Shady Grove Hospital with ambulance..
After receiving vaccine the patient was waiting for her 15 min. She began to report feeling of numbness in her fingers. Her vitals were checked and she had an elevated blood pressure of 200/108.  She was also was developing a redness on both arms and hands. Rechecking her blood pressure 5mins later her blood pressure was 190/110. Patent also had complaints of intermittent chest pain. After speaking to a provider it was decided to send patient to the ER to treat the elevated blood pressure.
Discharge Provider: DO Primary Care Provider: DO Admission Date: 9/26/2022 Discharge Date: Sep 28, 2022  PRESENTING PROBLEM: COVID-19    HOSPITAL COURSE: 89-year-old female with PMH significant for hypertension presenting for shortness of breath and some sputum production found to be in AFib with RVR (new onset A fib) and COVID positive.  Mild AKI upon presentation.    In the ED, received one dose 40 mg Lasix due to elevated NT proBNP and possible pulmonary vascular congestion on CXR. Elevated troponin was likely secondary to demand ischemia in setting of AFib with RVR, astropes normalized. Echo on 9/26 : EF = 55%; decreased from 60% on 4/30/21.   Patient was started on metoprolol for atrial fibrillation, titrated up to metoprolol XL 100 mg BID upon discharge. Heart rate remained stable in low 90s. Expect this will continue to improve as her COVID symptoms improve.    Patient's home hypertension medications were held - losartan and novasc - due to AKI on admission that has since resolved. Did not restart these medications going home, now that patient will be on metoprolol XL 100 mg BID. Should follow up outpatient with PCP for continued medication management.    Patient first started on Eliquis 5 mg BID for anticoagulation for atrial fibrillation, but had increased bruising on her arms, so was switched to Eliquis 2.5 mg BID. Patient was near the age and weight cut off for the dosing. Patient to only take meloxicam (home medication) as needed for pain, not daily, due to increase risk of bleeds.    Patient also receiving prescription upon discharge for an anti-viral medication for COVID (molnupiravir).    Patient stable upon discharge, back to patient's assisted living facility
Vision distortion; This is a spontaneous report from a non-contactable other healthcare professional, the patient. A 30-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: FC3180) via an unspecified route of administration in the left arm on 09Sep2021 at 13:30 (at the age of 30-years-old), as a single dose for COVID-19 immunisation. Medical history included multiple sclerosis. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccine within four weeks prior to the COVID vaccine. Concomitant medications included teriflunomide (AUBAGIO) 14mg and phentermine hydrochloride, topiramat (QSYMIA) 7.5mg; both for unspecified indications, from an unknown date and unknown if ongoing. On an unknown date in Sep2021, the patient experienced vision distortion. The events did not result in doctor or other healthcare professional office/clinic, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event vision distortion was not resolved at the time of this report.   No follow-up attempts are possible. No further information is expected.
pretty sick for a day; sore arm after second dose; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION COMPLICATION (pretty sick for a day) and VACCINATION SITE PAIN (sore arm after second dose) in a 67-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Blood pressure high, Cholesterol, Gout and Arthritis.    On 14-Mar-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. In March 2021, the patient experienced VACCINATION COMPLICATION (pretty sick for a day). In 2021, the patient experienced VACCINATION SITE PAIN (sore arm after second dose). At the time of the report, VACCINATION COMPLICATION (pretty sick for a day) and VACCINATION SITE PAIN (sore arm after second dose) outcome was unknown.            Patient took high blood pressure medication, cholesterol medication, gout medication and arthritis medication.  Treatment information was not provided by reporter.   This case was linked to MOD-2021-370192, MOD-2021-370208 (Patient Link).
This spontaneous report was received from a pharmacist concerning a 70 year old female patient with no pertinent medical history. Patient current condition included sulfa and naloxone allergy. On 03-OCT-2012, the patient was vaccinated with a dose of 0.65 milliliter ZOSTAVAX, subcutaneously in the left arm. Lot number and expiry date was reported as H011430 and 12-SEP-2013 respectively. No concomitant medications were reported. On 05-OCT-2012, the patient entire left arm was red, itchy, swollen and tender to the touch. The patient called to the pharmacist and visited to her daughter who was a nurse. The patient was treated with hot compress, hydrocortisone and BENADRYL cream. No laboratory studies were performed. The outcome of entire left arm was red, itchy, swollen and tender to the touch was reported as resolving as the swelling and itching went down and localized at injection site. The relatedness for entire left arm was red, itchy, swollen and tender to the touch was unknown for ZOSTAVAX. Additional information has been requested.
A tingling/numbness began at her hand in her right arm and continued upward toward her face and then a pain progressed down to chest.  Her speech was impaired, almost as if her tongue was swollen.  Also, she was confused and began mixing up words.  ie) tried to say "my arm hurts" but said "my fan hurts".  She understood she was mixing up her words and then would correct herself.  This is a display of stroke like symptoms.  She continued to have a headache and stomach ache and diarrhea for several days after this episode.  She was healthy prior to receiving the vaccination.
pt recv vax 15APR96 & 16APR96 mild fever, on 18APR96 devel fever of 106 per mom-saw MD cont fever until 21APR-went to ER, no illness found;22APR MD hosp for 24hr;MD stated this was probably vax rxn since no illness or cause for fever;
Left proximal bicep myalgia, pain from shoulder to neck, difficulty using arm to pull objects, pain increase with movement.